Ferenc Martenyi M.D., Ph.D.
About Ferenc Martenyi M.D., Ph.D.
Ferenc Martenyi M.D., Ph.D. serves as the Vice President and Head of Clinical Development at Prothena Corporation plc, where he has worked since 2019. He specializes in neurodegeneration with a focus on psychiatry and neurology, and has extensive experience in drug development across various regions.
Work at Prothena
Ferenc Martenyi serves as the Vice President and Head of Clinical Development at Prothena Corporation plc, a position he has held since 2019. Located in South San Francisco, he oversees clinical development strategies and initiatives. His role involves integrating discovery and clinical execution to enhance drug development processes. Martenyi's leadership contributes to Prothena's focus on advancing therapies for neurodegenerative diseases.
Education and Expertise
Ferenc Martenyi earned his MD from Semmelweis University, where he studied at the School of Medicine from 1977 to 1983. His educational background provides a strong foundation for his specialization in neurodegeneration, particularly in psychiatry and neurology. He possesses a deep understanding of the interdependence between discovery, clinical development, and execution in drug development, which informs his strategic decisions in clinical programs.
Background in Pharmaceutical Industry
Martenyi has extensive experience in the pharmaceutical industry, having held various positions at notable companies. He worked at Eli Lilly and Company as a Medical Fellow from 2008 to 2013 and later served as Regional Medical Operations in Vienna, Austria from 1995 to 2001. His career also includes roles at Novartis Pharmaceuticals in Basel, Switzerland, and Takeda Pharmaceuticals as Senior Medical Director from 2014 to 2017. He was a Senior Medical Director at Aptinyx Inc. from 2018 to 2019 and at AbbVie from 2013 to 2014.
Achievements in Drug Development
Throughout his career, Ferenc Martenyi has demonstrated expertise in integrating key information into decisions and plans, ensuring the success of clinical programs. His extensive experience spans multiple regions, including the US, Europe, and Japan, allowing him to navigate diverse regulatory environments and market needs. His focus on neurodegeneration has positioned him as a significant contributor to advancements in the field.